3-丙基苯胺 | 2524-81-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 3-丙基苯胺
• 英文名称: 3-propylaniline
• 英文别名: 3-Propyl-anilin；3-n-Propyl-aniline
• CAS: 2524-81-4
• 化学式: C₉H₁₃N
• mdl: MFCD00833403
• 分子量: 135.209
• InChiKey: IPWGAPCYYMTTLT-UHFFFAOYSA-N

物化性质

• 沸点：
  230 °C
• 密度：
  0.958±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  10
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.333
• 拓扑面积：
  26
• 氢给体数：
  1
• 氢受体数：
  1

安全信息

• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335
• 储存条件：
  室温

反应信息

• 作为反应物：
  描述：

  3-丙基苯胺 生成 3-propylbenzonitrile
  参考文献：
  名称：

  REPORT OF THE INTERNATIONAL CONSENSUS DEVELOPMENT CONFERENCE ON FEMALE SEXUAL DYSFUNCTION: DEFINITIONS AND CLASSIFICATIONS

  摘要：

  Purpose: Female sexual dysfunction is highly prevalent but not well defined or understood. We evaluated and revised existing definitions and classifications of female sexual dysfunction.Materials and Methods: An interdisciplinary consensus conference panel consisting of 19 experts in female sexual dysfunction selected from 5 countries was convened by the Sexual Function Health Council of the American Foundation for Urologic Disease. A modified Delphi method was used to develop consensus definitions and classifications, and build on the existing framework of the International Classification of Diseases-10 and DSM-TV: Diagnostic and Statistical Manual of Mental Disorders of the American Psychiatric Association, which were limited to consideration of psychiatric disorders.Results: Classifications were expanded to include psychogenic and organic causes of desire, arousal, orgasm and sexual pain disorders. An essential element of the new diagnostic system is the "personal distress" criterion. In particular, new definitions of sexual arousal and hypoactive sexual desire disorders were developed, and a new category of noncoital sexual pain disorder was added. In addition, a new subtyping system for clinical diagnosis was devised. Guidelines for clinical end points and outcomes were proposed, and important research goals and priorities were identified.Conclusions: We recommend use of the new female sexual dysfunction diagnostic and classification system based on physiological as well as psychological pathophysiologies, and a personal distress criterion for most diagnostic categories.

  DOI：

  10.1016/s0022-5347(05)67828-7
• 作为产物：
  描述：

  1-硝基-3-丙基-苯 生成 3-丙基苯胺
  参考文献：
  名称：

  REPORT OF THE INTERNATIONAL CONSENSUS DEVELOPMENT CONFERENCE ON FEMALE SEXUAL DYSFUNCTION: DEFINITIONS AND CLASSIFICATIONS

  摘要：

  Purpose: Female sexual dysfunction is highly prevalent but not well defined or understood. We evaluated and revised existing definitions and classifications of female sexual dysfunction.Materials and Methods: An interdisciplinary consensus conference panel consisting of 19 experts in female sexual dysfunction selected from 5 countries was convened by the Sexual Function Health Council of the American Foundation for Urologic Disease. A modified Delphi method was used to develop consensus definitions and classifications, and build on the existing framework of the International Classification of Diseases-10 and DSM-TV: Diagnostic and Statistical Manual of Mental Disorders of the American Psychiatric Association, which were limited to consideration of psychiatric disorders.Results: Classifications were expanded to include psychogenic and organic causes of desire, arousal, orgasm and sexual pain disorders. An essential element of the new diagnostic system is the "personal distress" criterion. In particular, new definitions of sexual arousal and hypoactive sexual desire disorders were developed, and a new category of noncoital sexual pain disorder was added. In addition, a new subtyping system for clinical diagnosis was devised. Guidelines for clinical end points and outcomes were proposed, and important research goals and priorities were identified.Conclusions: We recommend use of the new female sexual dysfunction diagnostic and classification system based on physiological as well as psychological pathophysiologies, and a personal distress criterion for most diagnostic categories.

  DOI：

  10.1016/s0022-5347(05)67828-7

文献信息

• 一种制备硫代酰胺的新方法
  申请人：湖南大学

  公开号：CN107365270B

  公开（公告）日：2020-07-28

  本发明揭示了一种硫代酰胺的制备方法，该方法以无金属催化剂单质碘作为催化剂，以二硫醚和胺类化合物作为反应底物在有机溶剂中，20‑140℃有效反应，在5‑20h的时间内，能高效、简便地得到硫代酰胺类化合物。该方法具有成本较低，产率高，操作简便、无污染等优点，对于实现其工业化生产具有一定的可行性。
• [EN] KINASE INHIBITORS AND METHOD OF TREATING CANCER WITH SAME<br/>[FR] INHIBITEURS DE KINASES ET PROCÉDÉ DE TRAITEMENT DU CANCER UTILISANT CEUX-CI
  申请人：UNIV HEALTH NETWORK

  公开号：WO2011123937A1

  公开（公告）日：2011-10-13

  The present teachings provide a compound represented by Strutural Formula (I): or a pharmaceutically acceptable salt thereof. Also described are a pharmaceutical composition and method of use thereof.

  本教学提供了一种由结构式(I)表示的化合物，或其药用可接受的盐。还描述了一种药物组合物及其使用方法。
• [EN] COMPOUNDS, COMPOSITIONS AND METHODS OF USE<br/>[FR] COMPOSÉS, COMPOSITIONS ET PROCÉDÉS D'UTILISATION ASSOCIÉS
  申请人：AQUINNAH PHARMACEUTICALS INC

  公开号：WO2020117877A1

  公开（公告）日：2020-06-11

  Herein, compounds, compositions and methods for modulating inclusion formation and stress granules in cells related to the onset of neurodegenerative diseases, musculoskeletal diseases, cancer, ophthalmological diseases, and viral infections are described.

  在这里，描述了用于调节与神经退行性疾病、肌肉骨骼疾病、癌症、眼科疾病和病毒感染相关的细胞中包涵体形成和应激颗粒的化合物、组合物和方法。
• Discovery and optimization of 2-phenyloxazole derivatives as diacylglycerol acyltransferase-1 inhibitors
  作者：Weiya Yun、Mushtaq Ahmad、Yingsi Chen、Paul Gillespie、Karin Conde-Knape、Sonja Kazmer、Shiming Li、Yimin Qian、Rebecca Taub、Stanley J. Wertheimer、Toni Whittard、David Bolin

  DOI：10.1016/j.bmcl.2011.09.039

  日期：2011.12

  In a discovery effort to find safe and effective DGAT-1 inhibitors, we have identified 2-phenyloxazole 4-carboxamide 1 as a conformationally constrained analog of a hydrazide hit, which was previously identified from high-throughput screening. Further optimization of this series has led to chemically more stable 2-phenyloxazole-based DGAT-1 inhibitor 25 with improved solubility, cell-based activity

  在寻找安全有效的DGAT-1抑制剂的发现工作中，我们已将2-苯基恶唑4-羧酰胺1确定为酰肼命中的构象受限类似物，先前已从高通量筛选中鉴定出了这种化合物。该系列的进一步优化已导致化学上更稳定的基于2-苯基恶唑的DGAT-1抑制剂25，具有改善的溶解度，基于细胞的活性和药代动力学特性。化合物25还在饮食诱导的肥胖症（DIO）大鼠模型中证明了体内功效。
• Development of LM98, a Small‐Molecule TEAD Inhibitor Derived from Flufenamic Acid
  作者：Léa Mélin、Shuay Abdullayev、Ahmed Fnaiche、Victoria Vu、Narjara González Suárez、Hong Zeng、Magdalena M. Szewczyk、Fengling Li、Guillermo Senisterra、Abdellah Allali‐Hassani、Irene Chau、Aiping Dong、Simon Woo、Borhane Annabi、Levon Halabelian、Steven R. LaPlante、Masoud Vedadi、Dalia Barsyte‐Lovejoy、Vijayaratnam Santhakumar、Alexandre Gagnon

  DOI：10.1002/cmdc.202100432

  日期：2021.10.6

  demonstrating the value of this transcription factor for the development of novel anti-cancer therapies. We report herein the design, synthesis and biological evaluation of LM98, a flufenamic acid analogue. LM98 shows strong affinity to TEAD, inhibits its autopalmitoylation and reduces the YAP-TEAD transcriptional activity. Binding of LM98 to TEAD was supported by 19F-NMR studies while co-crystallization

  YAP-TEAD 转录复合物负责调节癌细胞生长和增殖的基因的表达。由于 TEAD 的过表达导致 Hippo 通路的失调已在多种癌症中得到报道。TEAD 的抑制抑制了相关基因的表达，证明了这种转录因子对于开发新型抗癌疗法的价值。我们在此报告了氟灭酸类似物 LM98 的设计、合成和生物学评价。LM98 对 TEAD 显示出很强的亲和力，抑制其自棕榈酰化并降低 YAP-TEAD 转录活性。19支持 LM98 与 TEAD 的结合F-NMR 研究同时共结晶实验证实 LM98 锚定在 TEAD 的棕榈酸袋内。LM98 降低CTGF和Cyr61的表达，抑制 MDA-MB-231 乳腺癌细胞迁移并在细胞分裂期间将细胞周期阻滞在 S 期。